.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The COMPARE study directly compared standalone Hydrus Microstent with two iStent trabecular bypass devices in patients with open-angle glaucoma. The prospective multicenter randomized study found that Hydrus achieved a higher rate of complete surgical success at 12 months and produced greater reduction in glaucoma medication use. More patients in the Hydrus arm were medication-free at one year, while safety profiles were broadly similar. These findings illustrate that microinvasive glaucoma surgery is not a single homogeneous category: different devices have distinct mechanisms, implantation strategies, and pressure-lowering performance. For surgeons selecting MIGS, the practical question is not simply whether a device is minimally invasive but which trabecular pathway intervention is most appropriate for the eye and the intended treatment goal. The study also supports realistic counseling that medication reduction may be a more meaningful endpoint than dramatic IOP lowering in selected earlier-stage disease. Patient expectations, angle anatomy, cataract status, baseline medication burden, and reimbursement or access considerations remain relevant when integrating MIGS into an individualized glaucoma pathway.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The COMPARE study directly compared standalone Hydrus Microstent with two iStent trabecular bypass devices in patients with open-angle glaucoma. The prospective multicenter randomized study found that Hydrus achieved a higher rate of complete surgical success at 12 months and produced greater reduction in glaucoma medication use. More patients in the Hydrus arm were medication-free at one year, while safety profiles were broadly similar. These findings illustrate that microinvasive glaucoma surgery is not a single homogeneous category: different devices have distinct mechanisms, implantation strategies, and pressure-lowering performance. For surgeons selecting MIGS, the practical question is not simply whether a device is minimally invasive but which trabecular pathway intervention is most appropriate for the eye and the intended treatment goal. The study also supports realistic counseling that medication reduction may be a more meaningful endpoint than dramatic IOP lowering in selected earlier-stage disease. Patient expectations, angle anatomy, cataract status, baseline medication burden, and reimbursement or access considerations remain relevant when integrating MIGS into an individualized glaucoma pathway.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
